The wearable injectors industry contributes $6.95 billion in 2021, and it is projected to advance at a rate of 12.6% from 2021 to 2030, to generate $20.21 billion in 2030. It is ascribed to rising health hazard concerns, led by conventional injectors, coupled with growing demand for conventional and novel drug molecules.
In addition, the rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular diseases, and favorable reimbursement policies are projected to boost the demand for wearable injectors in the coming years.
Infusion therapy costs around $35 billion in the specialty drug industry. The subcutaneous injection is the most popular administration route in various therapeutic areas, including hemophilia, cancer, autoimmune disorders, and multiple sclerosis. It accounts for 50% of the expenditure on specialty medicine in the U.S.
Furthermore, biological drugs are large molecules, and more viscous compared to other drugs. They cause lesser pain during injection. The usage of the biological molecules with pharmacokinetics and subcutaneous back pressure boosts the usage of the biological molecules.
The slow administration of the drug is required for reducing patient discomfort and improving the drug's performance. For example, immunoglobulins are used for administering large volumes, and therefore, the preferred method is subcutaneous delivery. Immunoglobulins are administered in a specialized clinic or in a hospital through insertion sets or syringe pumps.
The major players operating in the industry are; Medtronic plc, SteadyMed Ltd., Ypsomed Group, Unilife Corporation, Insulet Corporation, F.Hoffmann-La Roche Ltd., Johnson & Johnson, Becton, Dickinson, and Company, and West Pharmaceutical Services Inc.
Therefore, the rising demand for wearable injectors is led by the growing prevalence of chronic diseases.
No comments:
Post a Comment